---
title: "Illumina, Inc. (ILMN.US)"
type: "quote"
locale: "en"
url: "https://longbridge.com/en/quote/ILMN.US.md"
symbol: "ILMN.US"
name: "Illumina, Inc."
industry: "Life Sciences Tools and Services"
---

# Illumina, Inc. (ILMN.US)

| Item | Detail |
|------|--------|
| Industry | Life Sciences Tools and Services |
| Location | US Market |
| Website | [www.illumina.com](https://www.illumina.com) |

## Company Profile

Illumina, Inc. provides sequencing- and array-based solutions for genetic and genomic analysis in the Americas, Europe, Greater China, the Asia Pacific, the Middle East, and Africa. The company offers sequencing- and array-based instruments and consumables, which include reagents, flow cells, and li...

## Financial Score

> *Longbridge Financial Score™ — Proprietary multi-factor rating model by [Longbridge](https://longbridge.com). This score is independently calculated by Longbridge and is not affiliated with any third-party rating agency.*
> Updated: 2026-02-20T04:30:12.000Z

**Overall: C (0.41)**

**Industry**: Life Sciences Tools and Services

| Metric | Value |
|--------|-------|
| Industry Ranking | 17 / 62 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Blend - Stocks in which the company has both growth and mature businesses.
- **Scale**: Large - The company has stable operations, allowing for dependable long-term returns.

### Score Analysis

**Style Score**: 

#### Growth Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | -0.66% |  |
| Net Profit YoY | 169.50% |  |

#### Value Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| P/B Ratio | 6.74 |  |
| Dividend Ratio | 0.00% |  |


**Size Score**: 

#### Market Cap Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 18.35B |  |

#### Revenue Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue | 4.34B |  |


**Multi Score**: C

#### Profit Score: A

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | 33.36% | A |
| Profit Margin | 19.57% | A |
| Gross Margin | 68.25% | A |

#### Growth Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | -0.66% | D |
| Net Profit YoY | 169.50% | A |
| Total Assets YoY | 5.41% | B |
| Net Assets YoY | 14.75% | A |

#### Cash Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| Cash Flow Margin | 510.94% | C |
| OCF YoY | -0.66% | D |

#### Operating Score: B

| Indicator | Value | Rating |
|-----------|-------|--------|
| Turnover | 0.67 | B |

#### Debt Score: D

| Indicator | Value | Rating |
|-----------|-------|--------|
| Gearing Ratio | 59.02% | D |


```chart-data:radar
{
  "title": "Longbridge Financial Score - Illumina, Inc.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Profit",
      "grade": "A",
      "indicators": [
        {
          "name": "ROE",
          "value": "33.36%",
          "rating": "A"
        },
        {
          "name": "Profit Margin",
          "value": "19.57%",
          "rating": "A"
        },
        {
          "name": "Gross Margin",
          "value": "68.25%",
          "rating": "A"
        }
      ]
    },
    {
      "name": "Growth",
      "grade": "C",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "-0.66%",
          "rating": "D"
        },
        {
          "name": "Net Profit YoY",
          "value": "169.50%",
          "rating": "A"
        },
        {
          "name": "Total Assets YoY",
          "value": "5.41%",
          "rating": "B"
        },
        {
          "name": "Net Assets YoY",
          "value": "14.75%",
          "rating": "A"
        }
      ]
    },
    {
      "name": "Cash",
      "grade": "C",
      "indicators": [
        {
          "name": "Cash Flow Margin",
          "value": "510.94%",
          "rating": "C"
        },
        {
          "name": "OCF YoY",
          "value": "-0.66%",
          "rating": "D"
        }
      ]
    },
    {
      "name": "Operating",
      "grade": "B",
      "indicators": [
        {
          "name": "Turnover",
          "value": "0.67",
          "rating": "B"
        }
      ]
    },
    {
      "name": "Security",
      "grade": "D",
      "indicators": [
        {
          "name": "Gearing Ratio",
          "value": "59.02%",
          "rating": "D"
        }
      ]
    }
  ]
}
```

### Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
|------|------|--------|--------|-----------|----------|------|--------|
| 01 | ChromaDex (US.CDXC) | A | A | A | B | B | A |
| 02 | Agilent Tech (US.A) | A | C | B | C | C | B |
| 03 | Waters (US.WAT) | A | B | B | C | C | B |
| 04 | WuXi Biologics (US.WXXWY) | B | B | D | A | B | B |
| 05 | West Pharmaceutical (US.WST) | B | B | B | B | C | B |

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | 21.59 | 6/59 | 29.32 | 21.59 | 12.00 |
| PB | 6.74 | 47/59 | 8.08 | 6.62 | 5.62 |
| PS (TTM) | 4.22 | 33/59 | 4.53 | 3.55 | 3.05 |
| Dividend Yield | 0.00% | - | - | - | - |

## Institutional View

### Analyst Rating Distribution

> As of 2026-02-19T05:00:00.000Z

Total Analysts: **20**

| Rating | Count | Percentage |
|--------|-------|-----------|
| Buy | 8 | 40% |
| Overweight | 1 | 5% |
| Hold | 8 | 40% |
| Underweight | 2 | 10% |
| Sell | 1 | 5% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 117.54 |
| Highest Target | 195.00 |
| Lowest Target | 80.00 |

## References

- [Company Overview](https://longbridge.com/en/quote/ILMN.US/overview.md) - Shareholders, executives, business segments
- [Financials](https://longbridge.com/en/quote/ILMN.US/norm.md) - Income statement, balance sheet, cash flow, distribution plan
- [Topics & Discussions](https://longbridge.com/en/quote/ILMN.US/topics.md) - Community topics and discussions

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.